Marcus Capital LLC decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 14.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,575 shares of the life sciences company’s stock after selling 2,000 shares during the quarter. Illumina comprises approximately 1.7% of Marcus Capital LLC’s investment portfolio, making the stock its 28th largest holding. Marcus Capital LLC’s holdings in Illumina were worth $2,008,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Patriot Financial Group Insurance Agency LLC grew its position in shares of Illumina by 1.4% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock worth $528,000 after buying an additional 43 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Illumina by 41.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock worth $1,056,000 after buying an additional 1,800 shares during the period. Paradigm Asset Management Co. LLC grew its position in shares of Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the period. State of Tennessee Treasury Department grew its position in shares of Illumina by 7.8% during the 1st quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock worth $16,697,000 after buying an additional 7,040 shares during the period. Finally, Bank of Nova Scotia grew its position in shares of Illumina by 265.4% during the 1st quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock worth $14,710,000 after buying an additional 62,612 shares during the period. 93.34% of the stock is owned by institutional investors.

In related news, Director Jay T. Flatley sold 22,540 shares of the stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the sale, the director now directly owns 539,176 shares of the company’s stock, valued at $105,252,546.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Marc Stapley sold 2,000 shares of the stock in a transaction on Monday, June 12th. The shares were sold at an average price of $170.85, for a total value of $341,700.00. Following the sale, the executive vice president now directly owns 41,341 shares in the company, valued at $7,063,109.85. The disclosure for this sale can be found here. Insiders have sold 167,705 shares of company stock worth $31,544,118 over the last ninety days. 1.60% of the stock is currently owned by insiders.

Several analysts have recently commented on ILMN shares. Deutsche Bank AG set a $175.00 price objective on shares of Illumina and gave the stock a “hold” rating in a research report on Friday, July 28th. Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and raised their price objective for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. Morgan Stanley reaffirmed an “underweight” rating and set a $122.00 price objective (up previously from $115.00) on shares of Illumina in a research report on Monday, July 10th. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective for the company. in a research report on Wednesday, June 21st. Finally, Barclays PLC reaffirmed a “hold” rating and set a $150.00 price objective on shares of Illumina in a research report on Wednesday, July 19th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company’s stock. Illumina has a consensus rating of “Hold” and an average price target of $177.01.

TRADEMARK VIOLATION WARNING: “Illumina, Inc. (ILMN) Stake Lowered by Marcus Capital LLC” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/09/10/illumina-inc-ilmn-stake-lowered-by-marcus-capital-llc.html.

Illumina, Inc. (ILMN) traded down 0.25% during midday trading on Friday, hitting $209.68. The stock had a trading volume of 437,617 shares. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $211.27. The firm has a 50 day moving average of $192.45 and a 200 day moving average of $178.64. The firm has a market cap of $30.61 billion, a price-to-earnings ratio of 42.07 and a beta of 0.81.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company had revenue of $662 million for the quarter, compared to analysts’ expectations of $642.38 million. During the same period last year, the firm posted $0.86 earnings per share. Illumina’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts predict that Illumina, Inc. will post $3.65 EPS for the current year.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.